Xeris appoints Dr. Anh Nguyen as CMO; Ken Johnson retiring April 1, 2025

Xeris Biopharma Holdings, Inc.

Dr. Anh Nguyen named Chief Medical Officer effective Feb 24, 2025.
Ken Johnson, SVP Global Dev & Medical Affairs, to retire April 1, 2025.
Nguyen will lead Medical, Regulatory, Preclinical/Clinical Dev, Pharmacovigilance.
Nguyen previously served as program medical lead for Gvoke NDA/MAA at Xeris.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ken Johnson

Senior Vice President, Global Development and Medical Affairs

XERS · Xeris Biopharma Holdings, Inc.

Effective: 2025-04-01
Filed: February 24, 2025, 6:59 PM ET

On February 24, 2025, Mr. Ken Johnson, Pharm.D. notified Xeris Biopharma Holdings, Inc. (the “Company”) of his decision to retire as Senior Vice President, Global Development and Medical Affairs, effective as of April 1, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ken Johnson retired as Senior Vice President, Global Development and Medical Affairs at Xeris Biopharma Holdings, Inc..

Action: retired
Role: Senior Vice President, Global Development and Medical Affairs

Exact text from the filing

On February 24, 2025, Mr. Ken Johnson, Pharm.D. notified Xeris Biopharma Holdings, Inc. (the “Company”) of his decision to retire as Senior Vice President, Global Development and Medical Affairs, effective as of April 1, 2025.

View on SEC.gov

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-25-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.